The Pharmaletter
Sandoz
Latest Sandoz News
Generics
Swiss generics and biosimilars company Sandoz has issued a 500 million euros ($585 million) bond with a 12-year maturity and a 4.835% coupon, with proceeds earmarked for general corporate purposes including refinancing existing debt. 15 September 2026
Related News
Latest News & Features of interest to Sandoz
Biotechnology
UK precision oncology company Vivan Therapeutics and Ad Atomica, the London-based AI-native drug discovery firm, have announced a discovery collaboration. 16 September 2026
Pharmaceutical
The US Institute for Clinical and Economic Review (ICER) today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of US pharma major AbbVie’s tavapadon for Parkinson’s disease. 16 September 2026
Pharmaceutical
Israeli hybrid drug developer Remepy today announced the appointment of Dr Eran Harary as chief medical officer (CMO), effective October 1, 2026. 16 September 2026
Pharmaceutical
US clinical-stage biopharma Sling Therapeutics today announced the close of a $123 million Series C financing. The proceeds will support the continued clinical advancement of linsitinib, an oral small molecule inhibitor of IGF-1R (insulin-like growth factor 1 receptor), a validated target for the treatment of thyroid eye disease (TED). 16 September 2026
Pharmaceutical
New York, USA-based neuropsychiatric firm LB Pharmaceuticals yesterday announced the appointment of Dr Susan Kozauer as chief medical officer (CMO). 16 September 2026
Biosimilars
India’s Shilpa Biologicals has announced an exclusive Middle East and North Africa (MENA) strategic licensing and commercialization agreement with SPIMACO Bio of Saudi Arabia for portfolio of PD-1 inhibitor biosimilars across the Middle East and North Africa (MENA). 16 September 2026
Generics
Swiss generics and biosimilars company Sandoz has issued a 500 million euros ($585 million) bond with a 12-year maturity and a 4.835% coupon, with proceeds earmarked for general corporate purposes including refinancing existing debt. 15 September 2026
Biotechnology
UK pharma major GSK today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. 15 September 2026
Pharmaceutical
Italy's Chiesi Group, a family-owned biopharma company focused on respiratory health, rare diseases and specialty care, has appointed David Khougazian as group chief executive officer (CEO). 15 September 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Revolution Medicines Rasonque (daraxonrasib), the company’s RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. 15 September 2026
Latest In Brief for Sandoz
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze